Quick Facts
Plain-English Summary
Dihexa was discovered through a rational drug design program aimed at developing angiotensin IV (Ang IV) analogues with improved blood-brain barrier penetration and pharmacokinetic stability. The parent compound Ang IV has cognition-enhancing effects in rodents but is rapidly degraded in plasma. Dihexa's hybrid structure gives it exceptional metabolic stability — a plasma half-life of 8–13 days — which is virtually unheard of for a peptidic compound.
The compound's primary mechanism is potentiation of hepatocyte growth factor (HGF) binding to its receptor c-Met. In hippocampal slice assays, Dihexa drives synaptogenesis with extraordinary potency — reportedly 7 orders of magnitude (10 million times) more potent than BDNF in these assays. In spatial learning tasks (Morris Water Maze, radial arm maze), Dihexa-treated rats significantly outperformed controls and showed improvements comparable to those seen in young animals vs cognitively aged ones.
No human clinical trial data exists. The compound has never been tested in a Phase I safety trial in humans. Its mechanism — potent c-Met agonism — raises theoretical oncology concerns because c-Met is a proto-oncogene, and sustained c-Met activation is associated with promotion of several cancer types. This concern is not established as a clinical risk but has prevented commercial development.
The nootropic community self-experiments with Dihexa primarily via transdermal cream (as it reportedly penetrates skin) at doses of 1–10mg. The extreme half-life means effects (and any toxicity) accumulate over weeks. Self-reported cognitive improvements are common in anecdotal reports, but without objective testing, placebo effect cannot be ruled out.
Dihexa is one of the least-characterized compounds with the most extreme vendor claims in the nootropic space. The 7-million-times-more-potent-than-BDNF figure is from an in vitro hippocampal slice assay — not a human cognition measure. The long half-life means errors in dosing are slow to reverse. The c-Met proto-oncogene concern is theoretical but unrefuted. Anyone considering this compound should understand they are operating in a complete human safety data vacuum.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Aged rat — Morris Water Maze | Dihexa (1 mg/kg SC × 7 days) improved spatial memory performance in aged cognitively impaired rats to levels comparable to young unimpaired animals. Synapse density increased in hippocampal CA1. McCoy et al. 2013 ↗ | Preclinical |
| Hippocampal slices — synaptogenesis | Dihexa potentiated HGF-induced spinogenesis with EC50 ~10⁻¹⁵ M — 10 million-fold more potent than BDNF in the same assay. Not a brain-wide cognition measure — an in vitro cell culture comparison. | Preclinical |
| Rat — scopolamine amnesia model | Dihexa reversed scopolamine-induced memory impairment in radial arm maze task; effects persisted for weeks after dosing, consistent with long plasma half-life. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| No human trials | — | — | No Data |
| No IND | — | — | No Data |
| Preclinical only | Animal models | — | Preclinical |
DIHEXA has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Only pharmacological data is from rats. No human safety data exists at any dose. The extreme half-life means if adverse effects occur, they may persist for weeks after stopping. Theoretical c-Met proto-oncogene concern is biologically plausible but unquantified.
Long-term safety completely unknown. c-Met is overexpressed in many cancers — sustained potent agonism is a theoretical cancer promotion risk. No immunotoxicity, reproductive toxicity, or genotoxicity data in humans or in standard preclinical safety package.
- Anxiety or dysphoria (reported by minority of users)
- Headache
- Vivid dreams / sleep disturbance
- Unknown — no systematic adverse event data collection
- Any personal or family history of cancer (c-Met proto-oncogene concern)
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Children and adolescents
- Immunosuppressed individuals
DIHEXA is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of DIHEXA for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of September 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
3 weeks on Dihexa cream 2mg/day. Subjective: word recall is faster, conversations feel more fluid. Hard to separate placebo from real effect without testing. The 2-week half-life is concerning — if something goes wrong you're just waiting it out.
The c-Met proto-oncogene thing bothers me more than people discuss. HGF/c-Met is a driver of tumor growth in gastric, liver, lung cancers. We're essentially chronically activating this pathway. Maybe fine. Maybe not. Zero data to answer the question.
I ran it for 4 weeks and then stopped. Still felt effects 3 weeks later. That's the half-life — accumulation means you can't just stop and feel normal quickly. Dose conservatively. Don't stack with other synaptogenic compounds until you know how you react.
People cite the '7 million times more potent than BDNF' stat constantly. Source is a hippocampal SLICE assay — basically a brain in a dish. The same metric doesn't translate to 'I am now 7 million times smarter.' Rodent spatial maze improvement is interesting but very different from complex human cognition.